Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Crown

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTCA J Croockewit, M H Bronchud, M S Aapro, et al.
Breast (Edinburgh, Scotland)|October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial designW Eiermann, J Bergh, F Cardoso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II studyC Hudis, M Fornier, L Riccio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2016
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trialJ R Mackey, T Pieńkowski, J Crown, et al.
Breast Cancer Research and Treatment|November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelA Di Leo, S Chan, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trialC Oakman, P A Francis, J Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancerS Chan, K Friedrichs, D Noel, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Breast Cancer Research and Treatment|May 13, 2021
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancerA J Eustace, S F Madden, J Fay, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTCA J Croockewit, M H Bronchud, M S Aapro, et al.
Breast (Edinburgh, Scotland)|October 11, 2011
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial designW Eiermann, J Bergh, F Cardoso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II studyC Hudis, M Fornier, L Riccio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2016
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trialJ R Mackey, T Pieńkowski, J Crown, et al.
Breast Cancer Research and Treatment|November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelA Di Leo, S Chan, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trialC Oakman, P A Francis, J Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancerS Chan, K Friedrichs, D Noel, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Breast Cancer Research and Treatment|May 13, 2021
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancerA J Eustace, S F Madden, J Fay, et al.
Pageof 11